The New Jersey Department of Health and the Centers for Disease Control and Prevention recommend that:

This patient should be placed on **Contact Precautions**

(Note: Nursing homes may implement Enhanced Barrier Precautions, if appropriate)

This patient has been identified OR awaiting to be ruled out colonization or infection with a novel or targeted multidrug-resistant organism (MDRO). Novel and targeted MDROs may cause long-lasting outbreaks in healthcare facilities and can live in the environment without proper cleaning and disinfection. Implementation of appropriate Transmission-Based Precautions is necessary to prevent outbreaks. Enhanced Barrier Precautions is not intended for use in acute care or long-term acute care hospitals but is intended for nursing homes for use as part of a containment strategy for novel and targeted MDROs. Contact Precautions should be implemented at acute care hospitals; when there is presence of acute diarrhea, draining wounds, secretions or excretions that are unable to be covered or contained, Contact Precautions should be implemented at both acute and long-term care settings.

Additional recommendations include:

- This patient should be placed in a **private room**, if available*
- Healthcare personnel interacting with patients on **Contact Precautions**, or their environment, are required to wear **gowns and gloves**
- Healthcare personnel interacting with patients on **Enhanced Barrier Precautions** are required to **wear gowns and gloves** during specific high-contact resident care activities
- Healthcare personnel should conduct diligent **hand hygiene** during and after contact with this patient/environment; Ensure **alcohol-based hand rub** is readily available
- **All cleaning and disinfection** should be performed an product appropriate for the novel or targeted MDRO. For example, units who house an individual colonized or infected with *Candida auris* should utilize a disinfectant with an **Environmental Protection Agency (EPA) registered disinfectant effective against Candida auris (List P) or C. difficile (List K)**. Environmental cleaning should include:
  - **All equipment** should be cleaned and disinfected after contact with this patient (e.g. stethoscopes, X-ray machines, respiratory therapy equipment)
  - **This patient’s room** should be cleaned and disinfected daily and terminally upon discharge
  - **Transport vehicles/equipment** should be terminally cleaned and disinfected after use
- Ensure written and verbal **communication** of isolation status for intra- and inter-facility transfers
- Upon admission, contact the NJ Department of Health Communicable Disease Service at **DOH.CDS.HAIAR.EPI@doh.nj.gov** to discuss infection prevention and control plan

*If a patient cannot be placed in a private room, please ensure their roommates are at low risk of developing Candida infections. (e.g., are not on antifungal therapies, no indwelling devices, no open wounds)

This form is to be used with the New Jersey Universal Transfer Form HFEL-7 available at [https://healthapps.state.nj.us/forms/](https://healthapps.state.nj.us/forms/)

**Resources**

3) PPE in Nursing Homes to Prevent MDROs | HAI | CDC. [https://www.cdc.gov/hai/containment/PPE-Nursing-Homes.html#1](https://www.cdc.gov/hai/containment/PPE-Nursing-Homes.html#1)
5) Inter-facility IC Transfer Form. [https://www.cdc.gov/hai/pdf/toolkits/Interfacility-IC-Transfer-Form-508.pdf](https://www.cdc.gov/hai/pdf/toolkits/Interfacility-IC-Transfer-Form-508.pdf)

May 2022
Target and Novel Multidrug-resistant Organism Case Transfer Information Sheet

This case status is: (check one)

☐ Confirmed: A novel or targeted MDRO was isolated from a body site

☐ Under investigation*: A novel or targeted MDRO is being ruled-out or needs to be ruled out as a result of a known exposure (NOTE: this is not a confirmed case but should be treated as such until negative results are received)

☐ Laboratory results are pending
☐ Colonization testing is needed

If patient is confirmed to have a novel or targeted MDRO, check one:

☐ Infection: Identification during clinical testing

☐ Infection has been treated and in remission
☐ Treatment is ongoing

☐ Colonization: Identification during surveillance testing

If patient is confirmed to have a novel or target MDRO with a diagnosed organism, check the implicating organism:

☐ Acinetobacter spp.  ☐ Candida auris  ☐ Enterobacter spp.
☐ Enterococcus spp.  ☐ Escherichia coli  ☐ Klebsiella pneumoniae
☐ Pseudomonas aeruginosa  ☐ Other: ________________________________

If patient is confirmed to have a novel or target MDRO with an identified carbapenemase gene, check the specific gene:

☐ IMP  ☐ KPC  ☐ NDM  ☐ VIM  ☐ OXA-23  ☐ OXA-24/40
☐ OXA-48  ☐ OXA-58  ☐ Other: ________________________________

The organism was isolated from the patient’s: (check all that apply)

☐ Skin  ☐ Blood  ☐ Urine  ☐ Respiratory Tract  ☐ Wound
☐ Stool  ☐ Other: ________________________________

The Isolation/Transmission-Based Precaution status at time of discharge:

☐ Contact  ☐ Droplet  ☐ Airborne  ☐ Enhanced Barrier

Additional notes:_________________________________________________________________________________________________________

*Please contact NJDOH CDS at DOH.CDS.HAIAR.EPI@dooh.nj.gov if laboratory testing is needed, or if pending laboratory results are not received within 10 days of transfer.

May 2022